Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT	
NATURE OF CONVEYANCE:	Corrective Assignment to correct the order of the first inventor's name previously recorded on Reel 017526 Frame 0704. Assignor(s) hereby confirms the first inventor's correct name is Ruggero Fariello.	

CONVEYING PARTY DATA

Name	Execution Date
Ruggero Fariello	10/12/2009

RECEIVING PARTY DATA

Name:	Newron Pharmaceuticals S.P.A.	
Street Address:	reet Address: Via Ludovico Ariosto 21	
City: Bresso (MI)		
State/Country:	State/Country: ITALY	
Postal Code:	20091	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number: 10559982	

CORRESPONDENCE DATA

Fax Number: (650)813-4848

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 650-813-4800

Email: paula.hurley@dechert.com

Correspondent Name: Dechert LLP
Address Line 1: PO Box 390460

Address Line 4: Mountain View, CALIFORNIA 94039-0460

ATTORNEY DOCKET NUMBER:	373987-011US (102895)	
NAME OF SUBMITTER:	Daniel M. Becker	

Total Attachments: 4

source=Corrective Assignment#page1.tif source=Corrective Assignment#page2.tif source=Corrective Assignment#page3.tif

PATENT 500987976 REEL: 023369 FRAME: 0681

10559982

CH 540 00

source=Corrective Assignment#page4.tif

PATENT REEL: 023369 FRAME: 0682

FORM PTO-1595 (Rev. 6-93) OMB No. 0651-0011 (exp. 4/94) 02-07-2006

103174473

SHEET

U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office

	Please record the attached original documents or copy thereof.				
1	Name of conveying party(ies):		Name and address of receiving party(ies)		
1.	Fariello Ruggero (executed December 19, 2005) Carlo Cattaneo (executed December 16, 2005) Patricia Salvati (executed December 16, 2005) Luca Benatti (executed December 16, 2005)		Name: Newron Pharmaceuticals, S.p.A. Address: Via Ludovico Ariosto, 21 1-20091 Bresso, Italy		
	Additional name(s) of conveying party(ies) attached?				
3.	Nature of conveyance:		Additional name(s) & address(es) attached?		
	Assignment				
4.	Application number(s) or patent number(s):				
	A. Patent Application No(s):	В.	. Patent No(s):		
	10/559,982		의 수 등		
	Additional numbers atta	ched?	1? ☐ Yes ☒ No		
5.	Name and address of party to whom correspondence Concerning document should be mailed:	6.	. Total number of applications and patents involved: [1]		
	Name: Ivor R. Elrifi, Esq.	7.	. Total fee (37 CFR 3.41) \$40.00		
	Address: MINTZ, LEVIN, COHN, FERRIS		☑ Enclosed		
	GLOVSKY and POPEO, P.C. One Financial Center Boston, MA 02111		The Commissioner is authorized to charge any additional deficiencies or credit any overpayment to Deposit Account No: 50-0311, Reference No. 26204-501 NATL.		
DO NOT USE THIS SPACE					
_					
9. Statement and signature To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.					
	Heidi A. Erlacher, Reg. No. 45,409	ku	February 2, 2006		
	Name of Person Signing Signate	ure	Date		
1	Total number of pages including cover sheet, attachments, and document: [5]				

Mail documents to be recorded with required cover sheet information to:

Mail Stop Assignment Recordation Services 2/2896 LMELLER 6868127 18559982 Director of the US Patent and Trademark Office / 2886 LMELLER 6868127 18559982

PO Box 1450 Alexandria, VA 22313-1450 81 FC:8821

ASSIGNMENT CONFIRMATION AGREEMENT

This ASSIGNMENT CONFIRMATION AGREEMENT (this "Agreement") is made and entered into as of this 12 day of 2009, by and among Ruggero FARIELLO, residing at Via della Vittoria, 22, I-21016 Luino, ITALY ("Fariello"), and Newron Pharmaceuticals, S.p.A. ("Newron") (Fariello and Newron each referred to herein as a "Party" and collectively as "Parties").

WITNESSETH:

WHEREAS, Fariello is an inventor of methods for the treatment of Parkinson's disease, which methods and related discoveries are described in U.S. patent application serial no. 10/559,982, entitled "Methods for Treatment of Parkinson's Disease," filed with the United States Patent and Trademark Office on December 9, 2005 as the national phase under 35 U.S.C. § 371 of international application serial no. PCT/IB04/01408, filed April 8, 2004, which claims priority benefit to U.S. provisional application serial no. 60/462,205, filed April 11, 2003 (all, collectively, the "Invention");

WHEREAS, all rights in the Invention, including all rights in patent applications, patents and claims relating thereto, have been transferred from Fariello to Newron pursuant to an Agreement executed on December 19, 2005 by Fariello (the "Assignment"), recorded at reel/frame 017526/0704; and

WHEREAS the Assignment document reversed Fariello's given and family names, and the Parties hereto wish to confirm herein that all rights in the Invention, including all rights in patent applications, patents and claims relating thereto, are held by Newron.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

- 1. Affirmation. Each of the Parties acknowledges and agrees that:
- a. Newron is the sole owner of all right, title and interest in the Invention, including without limitation: (i) all patents and patent applications describing or claiming such Invention and all divisions, continuations, continuations-in-part, reissues, continuing patent applications, reexaminations, and extensions thereof, any counterparts claiming priority therefrom or common priority therewith, all foreign counterparts thereof, all certificates of invention, utility models, industrial design protection, design patent protection and other governmental grants or issuances therefore, including, without limitation, the U.S. patent application having serial no. 10/559,982 (collectively, the "Patents"); (ii) all records and files related to the Invention and the Patents; and (iii) all causes of action relating to the Invention and the Patents, including without limitation the right to sue and recover damages for future, present and past infringements of the Patent and to fully and entirely stand in the place of Fariello in all matters related thereto (collectively, the "Invention Rights");

Page 1 of 3

- b. The Invention Rights were transferred and assigned to Newron for good and valuable consideration, the receipt of which is hereby acknowledged, without limitation, as follows:
- i. <u>Transfer from Fariello to Newron</u>. Fariello and Newron acknowledge and agree that all Invention Rights of Fariello were assigned and transferred to Newron (or its predecessors) and its successors and assigns and Newron accepted such assignments or transfers pursuant to the Assignment;
- c. Fariello acknowledges and agrees that: (i) to the extent that any of the foregoing assignments and transfers of ownership of Invention Rights was or is defective, for good and valuable consideration, the receipt of which is hereby acknowledged, Fariello hereby sells, assigns, transfers, conveys and delivers to Newron, *nunc pro tunc* to the assignments or transfers described above, all of Fariello's right, title and interest in and to the Invention Rights, including, without limitation, the U.S. patent application having serial no. 10/559,982, the international application having serial no. PCT/IB04/01408, filed April 8, 2004, and the U.S. provisional application having serial no. 60/462,205, and Newron hereby accepts such sale, assignment, transfer, conveyance and delivery; and (ii) Fariello holds no further rights in the Invention Rights.
- d. Nothing herein is intended to modify the rights and obligations of the Parties, under law or contract, with respect to any remuneration or other payments paid or payable in connection with or as a result of the Invention or the participation of the undersigned in the development thereof.
- 2. Authorization and Further Assurances. Fariello hereby authorizes the U.S. Patent and Trademark Office and the respective patent office or governmental agency in each jurisdiction outside of the United States to issue any and all patents, certificates of invention, utility models or other governmental grants or issuances that may be granted upon or in connection with the Invention Rights, including, without limitation, the Patents, and the U.S. patent application having serial no. 10/559,982, in the name of Newron, as the assignee to Fariello's interest therein. Fariello agrees to execute and deliver such other documents and to take all such other actions as Newron, its successors and assigns may reasonably request to effect the terms of this Agreement and to execute and deliver any and all affidavits, testimonies, declarations, oaths, samples, exhibits, specimens and other documentation as may be reasonably required to effect the terms of this Agreement.

IN WITNESS WHEREOF, each of the Parties have executed this Agreement as of the day and year first above written.

Ruggero FARIELLO

Newron Pharmaceuticals, S.P.A.

WITNESSED

WITNESSED

15224976.3.BUSINESS

RECORDED: 10/14/2009